Drug Delivery Systems for Asthma and Pulmonary Diseases, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 233

Special Issue Editors

E-Mail Website
Guest Editor
Department of Biochemistry, Faculty of Biology, Universidad Complutense, 28040 Madrid, Spain
Interests: pulmonary surfactant; lung drug delivery; nanoparticles; liposomes; drug-membrane interactions; inhaled drugs; respiratory physiology; lipid/protein interactions; membrane proteins
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
International Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba 305-8576, Japan
Interests: cardiovascular immunology; ischemic insult; nanoparticle development; electron microscopy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The effect of first-pass metabolism on orally administered medications plus the requirement of solubility to increase absorption limit the effectiveness of various drugs during treatment. For decades, asthmatics have relied on nebulization and aerosols for delivery, but advances in polymerization and nucleic acid packaging have shown promise in the potential of lasting relief being provided by targeted therapies for the epithelial cells involved in asthmatic exacerbations. Other respiratory pathologies (including COVID-19) are benefiting or could also benefit from advanced inhalative therapies. Additionally, the liposomal delivery of therapeutics could increase the local and systemic bioavailability of active ingredients while reducing the effects of first-pass metabolism. Of particular interest is the packaging potential of biopolymers in delivering new therapies derived from monoclonal antibodies, as well as gel- or film-based applications for use in the lungs.

We invite you to submit research on the packaging of asthmatic medications and of drugs targeting other respiratory pathologies, on increases in delivery efficiency, and on the biochemical interactions between target cells and engineered delivery systems.

Prof. Dr. Jesus Perez-Gil
Dr. Bryan Mathis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • liposomes
  • nanocarrier
  • pH
  • hydrogel
  • asthma
  • polymeric scaffolds
  • encapsulation
  • solubility
  • microemulsification

Related Special Issue

Published Papers

This special issue is now open for submission.
Back to TopTop